Navigation Links
Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
Date:4/30/2009

ZURICH, Switzerland, April 30 /PRNewswire/ -- An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced today that this sought-after designation has been granted to its product candidate Fluidosomes-tobramycin, a therapeutic that will soon be tested in Phase II clinical trials. The company has now been granted orphan drug designation for this candidate in both Europe and the US.

Axentis Pharma (Switzerland) announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted the orphan drug designation to its lead product candidate Fluidosomes-tobramycin. This drug is a liposomal formulation of tobramycin, an innovative treatment for infections of the respiratory tract in patients with cystic fibrosis that is delivered directly to the site of infection via standard nebulizers. Pre-clinical and Phase I clinical studies support improved safety and efficacy profiles for Fluidosomes-tobramycin as compared to currently marketed treatments for infections of the respiratory tract in patients with cystic fibrosis.

The orphan drug designation is granted with respect to treatment of pulmonary infections caused by Pseudomonas aeruginosa, a bacterium that is one of the most common causes of infections of the respiratory tract in patients with cystic fibrosis. Axentis Pharmas product candidate received the orphan drug designation for the US only two months after the application and less than one year after orphan designation in Europe was transferred to the company. Dr. Helmut Brunar, company CEO and President, comments: "The orphan drug designation for the US is very good news for affected patients as well as for Axentis Pharma's shareholders. Together with the Orphan Drug Designation that was already achieved last year in Europe, the US
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Promising Cystic Fibrosis Compound on Track for Development
2. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
3. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
4. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
5. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
6. Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting
7. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
8. PTC Therapeutics Announces Data from Additional Clinical Studies of PTC124 in Cystic Fibrosis Confirming Activity
9. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
10. Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
11. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., MOUNTAINVIEW,Calif.,Nov.25/PRNewswire/-- Che...aldatafromtheCompany,sPROTECT-1(theProspectiveRand...fTraficet-EN(TM)(CCX282-B)inpatientswithmoderate-t...withafavorablesafetyandtolerabilityprofile.Thestud...ionofdiseaseseverityasdefinedasa70-pointdecreasein...
(Date:11/24/2009)..., PITTSBURGH,Nov.24/PRNewswire/-- ,, WHAT:Ro...arsfollowinganautoaccident,wasactuallyfullyconscio...ningAmericasegment.TheDynaVoxEyeMaxwasfeaturedinth...andotherconditionscanunlockcommunication. ,, WH...leonlineat www.dynavoxtech.com ,, WHO:Ro...
(Date:11/24/2009)..., MADISON,N.J.,Nov.24/PRNewswire-FirstCall/--Qu...eadingproviderofdiagnostictesting,informationandse...nnualPiperJaffrayHealthcareConferenceinNewYorkCity...2009at9:30a.m.EasternTime. ,, Duringtheconferen...growthtoapproximate3%,operatingincometoexceed18%of...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine 52317 1LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine 52317 2Novavax Announces Appointment of John J Trizzino as Senior Vice President International and Government Alliances 13127 1Novavax Announces Appointment of John J Trizzino as Senior Vice President International and Government Alliances 13127 2Biomarkers May Predict Alzheimers 52316 1Biomarkers May Predict Alzheimers 52316 2Biomarkers May Predict Alzheimers 52316 3
... Influenza Conference, HIGH WYCOMBE, England, June...re-clinical data showing how a new flu vaccine has...nfluenza, including,pandemic and annual, was prese...e Control of Influenza VI (Options) Conference, in...h will be published in the,European Journal of Imm...
...007-Active Biotech (OMX Nordic: ACTI),has presente...th,World Congress on Inflammation (<a target="_bla...flammation2007.dk ) held,in Copenhagen June 16-20*...evelopment of,57-57 for the treatment of SLE and s... Phase II clinical trials are planned to be,initia...
Other Medicine Technology:New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation 2
(Date:11/25/2009)...5/PRNewswire-USNewswire/--TheBlackAIDSInstituterec...iveleadershipfor2010. ,, ThenewBoardMembersarea...policy,law,finance,governmenthealthprograms,editor...romawiderangeofpersonalbackgroundsincludingbothhet...hemselves,andrepresentingmultipleagegroups. ,, ...
(Date:11/25/2009)...ndorsements,Business,andPressJoinEfforttoEducate ...-Onceagain,theNationalBipolarFoundationandtheMedic...Safe,tilStable"program,whichisnowbeingwidelyaccept....Today,theNationalBipolarFoundationreceivedaprocla...omtheLt.GovernorofLouisianaMitchLandrieu.TheNation...
(Date:11/25/2009)... evidence of a statistically significant survival ...se estrogen receptor (ER)-positive tumors had high...118 (ER-alpha S118-P), according to a brief commun...al of the National Cancer Institute . , Approxim...moxifen. Preclinical studies have shown that ER-al...
(Date:11/25/2009)...lood pressure? This simple question has been the ...ess-related gene Modulates High Blood Pressure in ... This simple question has been the focus of intens...or the first time established a link between a nov...e to stress in mice as well as humans. The studies...
(Date:11/25/2009)...to fight rheumatoid arthritis, could help newly di...SDAY, Nov. 25 (HealthDay News) -- A drug commonly ...d arthritis now also shows some promise in helping..., The drug, rituximab (Rituxan), helped patients ...ugh the disease had destroyed some of their pancre...
Breaking Medicine News(10 mins):Health News:Black AIDS Institute Announces 2010 Board Election Results 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
.... 31 Biopure Corporation,(Nasdaq: BPUR ) announc...ommon stock will revert from BPURD to BPUR at the ... Outstanding warrants that trade on the OTCBB,will...re Corporation develops, manufactures and markets ...
.../PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(TS...company focused on,endocrine therapy and oncology,...d operating results before market open on Wednesda...ants may,access the live webcast via the Company,s...
...ct. 31 Allos,Therapeutics, Inc. (Nasdaq: ALTH ),...pment and commercialization of small molecule ther...ced that Paul L. Berns, President and,CEO, will pr... (Eastern) on,Tuesday, November 6, 2007. There wil...
... a record $175 million; net book-to-bill of 1.7:1,...an all-time Company high, - Third quarter operat... - Third quarter EPS of $0.25 (GAAP) and $0.48...endle (Nasdaq: KNDL ), a,leading, global full-ser...
...DVENTRX Pharmaceuticals,Inc. (Amex: ANX ), a biop...used on commercializing proprietary product candid...seases, announced today that Evan M. Levine,ADVENT...The conference takes place in New York at the Wald...
...t. 30 Medical Services,International Inc. (OTC Pi...as added 4 additional distributors in the month of...utorships these corporations will have to purchase...,a Dengue Fever Kit and only one other manufacture...
Other Medicine News:Health News:Biopure's Stock Symbol Reverts to BPUR 2Health News:Allos Therapeutics to Present at the 2007 Acumen BioFin Rodman & Renshaw Conference 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 2Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 3Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 4Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 5Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 6Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 7Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 8Health News:Kendle Delivers Record Sales and Backlog and Strong Growth in Operating Margin for Third Quarter 2007 9Health News:ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference 2
...lly invasive treatment option for female patients ...The Monarc treats SUI by supporting the urethra du...ughing or laughing. Monarc's outside-to-in transob...c's transobturator approach and knitted, polypropy...
Uretex® Self-Anchoring Urethral Support System
Bard Dermal Allograft
NephroMax High Pressure Nephrostomy Balloon Catheters
Medicine Products: